Risk of Ischemic, Hemorrhagic Stroke Up With Type 1 Diabetes

Share this content:
Risk of Ischemic, Hemorrhagic Stroke Up With Type 1 Diabetes
Risk of Ischemic, Hemorrhagic Stroke Up With Type 1 Diabetes

TUESDAY, Dec. 13, 2016 (HealthDay News) -- The risks of ischemic and hemorrhagic stroke are increased with type 1 diabetes, with incrementally increasing risks with increasing hemoglobin A1c (HbA1c), according to a study published in the November issue of the Journal of Internal Medicine.

Christina Hedén Ståhl, from the University of Gothenburg in Sweden, and colleagues conducted a prospective, matched cohort study to examine the excess stroke risk in relation to glycemic control in patients with type 1 diabetes. Patients with type 1 diabetes registered in the Swedish National Diabetes Register (33,453 participants) were each matched to five control subjects from the general population (159,924 participants).

The researchers found that 2.3 percent of patients with diabetes and 0.7 percent of control subjects were diagnosed with stroke. Type 1 diabetes patients had overall multiple-adjusted hazard ratios of 3.29 and 2.49 for ischemic and hemorrhagic stroke, respectively, compared with control subjects. With increasing HbA1c, the risk of ischemic and hemorrhagic stroke increased incrementally; the risk of ischemic stroke was significantly increased with HbA1c within target (≤6.9 percent, multiple-adjusted hazard ratio, 1.89). The risks of ischemic and hemorrhagic stroke were markedly increased for HbA1c ≥9.7 percent, with multiple-adjusted hazard ratios of 7.94 and 8.17, respectively.

"Individuals with type 1 diabetes have an increased risk of ischemic and hemorrhagic stroke, increasing markedly with poor glycemic control," the authors write.

The Novo Nordisk Foundation provided some funding for the study.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »